The classic website will no longer be available as of June 25, 2024. Please use the modernized

Key Record Dates Identifier: NCT05609968
Brief Title: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

First Submitted : November 2, 2022
First Submitted that Met QC Criteria : November 2, 2022
First Posted : November 8, 2022

Last Update Submitted that Met QC Criteria : May 9, 2024
Last Update Posted : May 10, 2024